Feb 18, 2022
- Feb 17, 2023

Applying JAK Inhibitor Therapeutics to Improve Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis

EARNed Credits

1.0

AMA PRA Category 1 CreditTM

1.0

CNE Contact Hour

1.0

CPE Contact Hour

iStock-841843628

Overview

This CME/CE program is derived from content presented at the Maui Derm for Dermatologists 2022 Annual Meeting. The expert faculty, led by Lawrence Eichenfield, MD, will highlight the use of Janus kinases (JAK) inhibitor therapeutics to improve outcomes in patients with atopic dermatitis. The faculty will begin with an overview of current clinical trial data, including new and emerging therapies utilizing JAK-1 inhibitors, for the treatment of atopic dermatitis. Following, the practical applications of JAK-1 inhibitor therapeutics, pertaining to vaccinations and mitigating risk, will be analyzed. The faculty will conclude with a series of challenging cases presentations for improving outcomes for patients with atopic dermatitis.

Who Should Attend

Dermatologists, and dermatology advanced practice providers (NPs and PAs) who are involved in the care and treatment of patients with moderate-to-severe atopic dermatitis

Provided By

Course Faculty

Lawrence F. Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology Chief, Pediatric and Adolescent Dermatology University of California, San Diego Rady Children’s Hospital, San Diego San Diego, CA
Jonathan Silverberg, MD, PhD, MPH
Associate Professor Director of Clinical Research Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, DC
Eric Simpson, MD, MCR
Professor of Dermatology Department of Dermatology Oregon Health & Science University Portland, OR
Alyssa Wu, PharmD, BCPPS
Multidisciplinary AD Program Pharmacist Rady Children’s Hospital San Diego San Diego, CA

Learning Objectives

1

Understand the disease burden and therapeutic targets, including the JAK-1 receptor, for moderate-to-severe atopic dermatitis

2

Review recent JAK-1 inhibitor clinical trial data for the management of adolescents and adults with moderate-to-severe atopic dermatitis

3

Develop comprehensive treatment plans including a risk-benefit profile for JAK-1 receptor therapeutics and appropriate vaccinations to apply monoclonal antibody therapies to treat AD

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Lawrence F. Eichenfield, MD (Course Chair)
Consultant/AdvisorAbbVie; Almirall; Arcutis; Arena Pharmaceuticals, Aslan; Dermavant; Eli Lilly; Galderma; Incyte; Janssen; Leo Pharm; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron; Sanofi- Genzyme

Grant/Research Support: AbbVie; Amgen Inc.; Arcutis Biotherapeutics; Corevita; Eli Lilly; Incyte; Leo Pharma; Novartis; Pfizer Inc.; Regeneron; Sanofi- Genzyme; Trevi Therapeutics

Speakers Bureau: Incyte; Leo Pharm; Pfizer Inc.; Regeneron; Sanofi- Genzyme

Board of Directors: Forte; Verrica

Jonathan Silverberg, MD, PhD, MPH

 

 Consultant/Advisor: Abbvie; Afyx; Aobiome; Arena; Asana; Aslan; BioMX; Bluefin; Bodewell; Boehringer-Ingelheim; Celgene; Connect Biopharma; Dermavant; Dermira; Eli Lilly; Galderma; GlaxoSmithKline; Incyte; Kiniksa; Leo Pharma; Luna; Menlo; Novartis; Pfizer Inc.; RAPT; Regeneron; Sanofi-Genzyme

Speakers Bureau: Abbvie; Eli Lilly; Leo Pharma; Pfizer Inc.; Regeneron; Sanofi-Genzyme

 

Eric Simpson, MD, MCR 

 

Consultant/Advisor: AbbVie; Amgen Inc.; Arena Pharmaceuticals, Inc.; Benevolent AI Bio Limited; BiomX Ltd; Bluefin Biomedicine Inc; Boehringer-Ingelheim; Dermira; Eli Lilly; Evidera; ExcerptaMedica; Forte Bio RX; Galderma; GlaxoSmithKline; Incyte; Janssen; Kyowa Kirin Pharmaceutical Development; Leo Pharma; Novartis; Pfizer Inc.; Physicians World LLC; Regeneron; Roivant; Sanofi- Genzyme; Trevi Therapeutics; Valeant; WebMD

Grant/Research Support: AbbVie; Amgen Inc.; Arcutis Biotherapeutics; Corevita; Dermira; Eli Lilly; Incyte; Kyowa Kirin Pharmaceutical Development; Leo Pharma; Merck; Novartis; Pfizer Inc.; Regeneron; Sanofi- Genzyme; Trevi Therapeutics

Speakers Bureau: AbbVie; Eli Lilly; Leo Pharma; Pfizer Inc.; Regeneron; Sanofi- Genzyme

Alyssa Wu, PharmD, BCPPS Nothing to disclose

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Gabrielle Fiorelli, CRNP; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

 

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-22-002-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Pfizer Inc.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

Feb 18, 2022
- Feb 17, 2023

Applying JAK Inhibitor Therapeutics to Improve Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis

Related Webcast Courses

Allergy
Dermatology
Update on the Safety and Efficacy of JAK Inhibitor Therapeutics for the Treatment of Atopi...